RecruitingNCT06553625

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System

Sponsor

Boston Scientific Corporation

Enrollment

200 participants

Start Date

Jan 29, 2024

Study Type

OBSERVATIONAL

Conditions

Movement Disorders Parkinson Disease Dystonia Essential Tremor

Summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Eligibility

Inclusion Criteria2

Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)
Signed a valid, IRB/EC/REB-approved informed consent form

Exclusion Criteria2

Meets any contraindications per locally applicable Directions for Use (DFU)
Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Interventions

DEVICERadiofrequency Ablation

Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery

Locations(4)

Uniklinik Köln

Cologne, Germany

Universitaetsklinikum Dusseldorf

Düsseldorf, Germany

Universitaetsklinikum Wuerzburg

Würzburg, Germany

St. Georges Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06553625

Related Trials

Vestibular and Cortical Contributions to Transitions in Freezing of Gait in Parkinson's Disease

NCT065060581 location